Novavax COVID-19 Vaccine Recommended For Conditional Marketing Authorization In EU For Adolescents

Novavax COVID-19 Vaccine Recommended For Conditional Marketing Authorization In EU For Adolescents

LONDON — The European Medicines Agency said Thursday it is recommending the authorization of the coronavirus vaccine made by French pharmaceutical Valneva, making it the sixth shot given the green light in Europe. Those results showed Valneva’s vaccine triggered the production of higher levels of antibodies than the AstraZeneca vaccine. The EMA said “the (Valneva) vaccine is as effective at triggering the production of antibodies in people aged between 18 and 29 as it is in people aged 30 years and older.” Still, the EMA said there were limited data on how effective Valneva’s vaccine might be against the virus’ omicron variant and its subvariants, which are currently fueling surges of cases across Europe. The EMA said the side effects from Valneva’s shot were mostly mild, including aches, nausea and …
More on: www.washingtonpost.com